26 TWENTYFOURSEVENBIOPHARMA Issue 2 / June 2025 Overall, we’re here to help innovators get the right foundation in place so they can move forward with confidence. What are you hoping to achieve from the event? We’re really looking forward to BIO 2025 as a chance to reconnect with existing customers and meet new ones, especially those in the early stages of development. We’ve noticed significantly more interest in nasal delivery compared to previous years, which is great to see. It’s a space we know well, and we’re eager to explore how we can help new partners bring their ideas to life — whether it’s formulation support, spray testing, scale up, or full development through manufacturing. Beyond business development, BIO is also where we learn what’s coming next — trends, technologies, and what other innovators are focused on. It gives us the chance to share what we’ve been working on, but also to listen, learn, and understand how we can evolve our offerings to better support the biotech community. Ultimately, we’re there to build strong, long-term relationships and help promising therapies reach patients faster. How do you stay ahead of industry trends and developments in the pharmaceutical sector? Staying ahead in this industry really comes down to staying connected. We work closely with device manufacturers and key excipient suppliers, especially in the nasal space, which gives us early visibility into new technologies and upcoming market shifts. We’re often aware of product innovations before they hit the mainstream — and that helps us prepare internally. We’re also constantly reinvesting in new equipment and expanding our technical capabilities so we can support more complex programs and stay flexible as project needs evolve. On top of that, our team keeps a close eye on regulatory updates and industry best practices. All of this helps us not just react to change but get ahead of it. We’re always thinking about what’s next and how we can better support our partners as the industry continues to evolve. What challenges are you currently facing in the pharmaceutical market, and how are you addressing them? One of the biggest challenges we’re navigating right now is the uncertainty around tariffs, which is impacting material costs and complicating long-term planning. These increased costs ultimately affect our clients, so we’re doing everything we can to minimize the impact. We work closely with our suppliers to stay ahead of potential changes and identify cost-saving opportunities where possible. Internally, we’re building more flexibility into our sourcing strategies and timelines. We also maintain open, proactive communication with our clients — so they’re aware of potential cost shifts early and can make informed decisions. It’s a complex issue, but transparency and collaboration go a long way in helping everyone stay on track. What new products or innovations is your company showcasing at BIO 2025 this year? We are showcasing our proprietary chemoenzymatic ligation platform—an advanced synthetic technology that enables precise, scalable production of oligonucleotide therapeutics. This innovation supports the development of siRNAs, long RNAs such as sgRNA, and conjugates with superior purity, cost, and sustainability compared to traditional synthesis methods. What are you hoping to achieve from the event? BIO 2025 is an ideal forum to forge strategic partnerships, engage with emerging biotech innovators, and provide updates to our vertically integrated CDMO capabilities. We aim to accelerate collaboration on next-generation nucleic acid therapeutics and expand awareness of how our platform addresses key manufacturing and capacity challenges. How does your company stay ahead of industry trends and developments in the pharmaceutical sector? We invest heavily in R&D and maintain close collaborations with academic and industry leaders. This allows us to anticipate therapeutic trends, regulatory shifts, and emerging modalities - particularly within the field of RNA therapeutics - and ensure our technology and infrastructure evolve in lockstep with client and market needs. What challenges are you currently facing in the pharmaceutical market, and how is your organization addressing them? Key challenges include scaling novel modalities and ensuring regulatory compliance for complex constructs. Our chemoenzymatic platform addresses these by offering modular, high-fidelity synthesis, while our CDMO services provide robust process development, analytical and GMP infrastructure to support clinical and commercial readiness. DAVID BUTLER CTO Hongene Biotech | Global Nucleic Acid Raw Materials and CDMO Services BIO INTERNATIONAL CONVENTION
RkJQdWJsaXNoZXIy MjY2OTA4MA==